PCI expands cold chain storage capabilities at UK site
The announcement is the latest in a series of strategic investments at PCI, demonstrating its market-leading presence in Biotech therapies, supporting medicines destined reach to more than 100
The announcement is the latest in a series of strategic investments at PCI, demonstrating its market-leading presence in Biotech therapies, supporting medicines destined reach to more than 100
In this connection, the Bristol-Myers Squibb and Vedanta Biosciences, an affiliate of PureTech Health, have entered into a clinical collaboration. Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor,
The candidate, known as E2814, is an anti-tau monoclonal antibody set to be tested in human trials for the first time to assess its ability to slow the
The divested rights by the UK-based AstraZeneca to Covis Pharma cover markets outside the US and the US royalties for the three over-the-counter (OTC) drugs. In 2017, AstraZeneca
The recalled lots of the product have been found to potentially have higher concentrations of ibuprofen. There is a remote possibility that infants, who may be more susceptible
Phase III studies PEARL1 and PEARL 2 are planned to include more than 2,000 CSU patients. Charité-Universitätsmedizin Allergie-Centrum-Charité Department of Dermatology and Allergy Dermatology and Allergy Professor and
DeepMind further claimed that its AI-driven system, AlphaFold, is capable of generating 3D models of proteins that are highly accurate and potentially capable of solving one of the
Momenta had previously guided that it planned to file a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in the fourth quarter of this
Zolgensma was previously granted breakthrough therapy designation by the US regulator. Novartis expects a regulatory action to be taken on the gene replacement therapy in May 2019. According
The Series C financing round was led by the Redmile Group, with participation by new investor Rock Springs Capital and existing investors 5AM Ventures, Versant Ventures, HealthCap, Sectoral